Literature DB >> 7524522

CD20: a regulator of cell-cycle progression of B lymphocytes.

T F Tedder1, P Engel.   

Abstract

CD20 is a B-cell-specific cell-surface molecule with four membrane-spanning domains, as well as cytoplasmic N- and C-terminal domains. Here, Thomas Tedder and Pablo Engel discuss the suggestion that CD20 is a regulator of transmembrane Ca2+ conductance and plays an important functional role in B-cell activation, proliferation and differentiation.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7524522     DOI： 10.1016/0167-5699(94)90276-3

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  123 in total

Review 1.  Calcium channels in lymphocytes.

Authors:  G Grafton; L Thwaite
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

Review 2.  Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

Authors:  Nicole Selenko; Otto Majdic; Ulrich Jäger; Christian Sillaber; Johannes Stöckl; Walter Knapp
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

3.  Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.

Authors:  Efrat Dotan; Charu Aggarwal; Mitchell R Smith
Journal:  P T       Date:  2010-03

Review 4.  Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Jeremy M Clain; Rodrigo Cartin-Ceba; Fernando C Fervenza; Ulrich Specks
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

5.  Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

Authors:  Norihito Yazawa; Yasuhito Hamaguchi; Jonathan C Poe; Thomas F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-10       Impact factor: 11.205

Review 6.  Update on rituximab.

Authors:  R Eisenberg
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 7.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

Review 8.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

9.  Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).

Authors:  Tamás Schneider; András Rosta; Hajna Losonczy; Gáspár Radványi; György Ujj; Miklós Egyed; Árpád Illés; János Jakucs; László Szerafin; Zoltán Gasztonyi; Tamás Masszi; János Iványi; Judit Demeter; Péter Dombi; Antal Tóth; Zita Borbényi
Journal:  Pathol Oncol Res       Date:  2017-04-21       Impact factor: 3.201

10.  B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.

Authors:  Ikuko Hayakawa; Thomas F Tedder; Yuan Zhuang
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.